Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nkarta, Inc. NKTX
$4.50
+$0.03 (0.56%)
На 18:02, 12 мая 2023
+655.56%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
227535195.00000000
-
week52high
18.48
-
week52low
3.12
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.13869300
-
EPS
-2.65000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | Overweight | 12 авг 2022 г. |
| Needham | Buy | 28 июл 2022 г. | |
| SVB Leerink | Outperform | 18 июл 2022 г. | |
| Raymond James | Outperform | Outperform | 26 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 26 апр 2022 г. |
| Mizuho | Buy | Buy | 16 ноя 2022 г. |
| Oppenheimer | Outperform | Outperform | 10 ноя 2022 г. |
| Oppenheimer | Perform | Outperform | 22 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brandenberger Ralph | D | 28309 | 491 | 17 янв 2023 г. |
| Hager Alicia J. | D | 57197 | 1103 | 17 янв 2023 г. |
| HASTINGS PAUL J | D | 313106 | 3691 | 17 янв 2023 г. |
| Mahmood Nadir | D | 84302 | 1122 | 17 янв 2023 г. |
| Shook David | D | 60302 | 175 | 17 янв 2023 г. |
| Trager James | D | 98557 | 1115 | 17 янв 2023 г. |
| Hager Alicia J. | D | 75000 | 75000 | 13 янв 2023 г. |
| Hager Alicia J. | A | 58300 | 37500 | 13 янв 2023 г. |
| HASTINGS PAUL J | D | 386500 | 386500 | 13 янв 2023 г. |
| HASTINGS PAUL J | A | 316797 | 64500 | 13 янв 2023 г. |
Новостная лента
7 Cheap But Risky Biotech Stocks
Barrons
18 янв 2023 г. в 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
GlobeNewsWire
02 дек 2022 г. в 16:02
Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET
Nkarta: Under The Radar Company With Brilliant Results
Seeking Alpha
10 ноя 2022 г. в 12:02
NKTX came out with strong data in heavily pretreated AML patients in April. Data was at least as good as Fate's data, which is valued nearly 4x higher.
Nkarta to Participate at Upcoming Investor Conferences
GlobeNewsWire
02 ноя 2022 г. в 08:02
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:
7 Unknown Biotech Stocks That Could Rocket in 2023
InvestorPlace
23 сент 2022 г. в 07:30
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.